Home The Word Brain My Amedeo FAQ Privacy About   

2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.

  Lung Cancer

  Free Subscription

Articles published in Lancet

Retrieve available abstracts of 26 articles:
HTML format

Single Articles

    March 2024
  1. MUROYA D, Morimitsu Y, Nakamura K, Hayashi K, et al
    Hidden metastatic lung tumour diagnosed by AI.
    Lancet. 2024;403:1290.

  2. EDERHY S, Cadranel J, Granger C, Hammoudi N, et al
    Investigation of endocarditis finds advanced lung adenocarcinoma: both resolve after tyrosine kinase inhibitor treatment.
    Lancet. 2024;403:860-861.

    January 2024
  3. PAZ-ARES L, Mehta B, Wang Y, Obiozor C, et al
    Sotorasib in KRAS(G12C) mutated lung cancer - Authors' reply.
    Lancet. 2024;403:145-146.

  4. OLIVIER T, Prasad V
    Sotorasib in KRAS(G12C) mutated lung cancer.
    Lancet. 2024;403:145.

  5. HANNA GG, McDonald F
    SBRT for oligoprogressive disease: using the evidence to maximise the benefits.
    Lancet. 2024;403:122-124.

    December 2023
  6. CHU Q, Perrone F, Greillier L, Tu W, et al
    Pembrolizumab plus chemotherapy versus chemotherapy in untreated advanced pleural mesothelioma in Canada, Italy, and France: a phase 3, open-label, randomised controlled trial.
    Lancet. 2023;402:2295-2306.
    PubMed     Abstract available

  7. LEE YCG
    Pembrolizumab plus chemotherapy for pleural mesothelioma.
    Lancet. 2023;402:2266-2267.

  8. TSAI CJ, Yang JT, Shaverdian N, Patel J, et al
    Standard-of-care systemic therapy with or without stereotactic body radiotherapy in patients with oligoprogressive breast cancer or non-small-cell lung cancer (Consolidative Use of Radiotherapy to Block [CURB] oligoprogression): an open-label, randomi
    Lancet. 2023 Dec 14:S0140-6736(23)01857-3. doi: 10.1016/S0140-6736(23)01857.
    PubMed     Abstract available

    November 2023
  9. SALMAN M, Fernandez Crespo R, Judah G
    Impact of messaging informed by behavioural science on uptake of targeted lung health checks: a service evaluation.
    Lancet. 2023;402 Suppl 1:S82.
    PubMed     Abstract available

    July 2023
    Safe and effective systemic therapy for early-stage non-small-cell lung cancer.
    Lancet. 2023 Jul 18:S0140-6736(23)01464-2. doi: 10.1016/S0140-6736(23)01464.

  11. CHANG JY, Lin SH, Dong W, Liao Z, et al
    Stereotactic ablative radiotherapy with or without immunotherapy for early-stage or isolated lung parenchymal recurrent node-negative non-small-cell lung cancer: an open-label, randomised, phase 2 trial.
    Lancet. 2023 Jul 18:S0140-6736(23)01384-3. doi: 10.1016/S0140-6736(23)01384.
    PubMed     Abstract available

  12. O'SULLIVAN H, Popat S
    Atezolizumab in patients with advanced non-small-cell lung cancer who are platinum-doublet ineligible.
    Lancet. 2023 Jul 6:S0140-6736(23)00807-3. doi: 10.1016/S0140-6736(23)00807.

  13. LEE SM, Schulz C, Prabhash K, Kowalski D, et al
    First-line atezolizumab monotherapy versus single-agent chemotherapy in patients with non-small-cell lung cancer ineligible for treatment with a platinum-containing regimen (IPSOS): a phase 3, global, multicentre, open-label, randomised controlled stu
    Lancet. 2023 Jul 6:S0140-6736(23)00774-2. doi: 10.1016/S0140-6736(23)00774.
    PubMed     Abstract available

    April 2023
  14. SLATER S, Cunningham D
    Pembrolizumab plus chemotherapy as first-line treatment for advanced biliary tract cancer.
    Lancet. 2023 Apr 14:S0140-6736(23)00767-5. doi: 10.1016/S0140-6736(23)00767.

    February 2023
  15. GOLDBERG SB, Herbst RS
    The end of the beginning: progress and next steps in KRAS-mutant non-small-cell lung cancer.
    Lancet. 2023 Feb 9:S0140-6736(23)00288-X. doi: 10.1016/S0140-6736(23)00288.

  16. DE LANGEN AJ, Johnson ML, Mazieres J, Dingemans AC, et al
    Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRAS(G12C) mutation: a randomised, open-label, phase 3 trial.
    Lancet. 2023 Feb 7:S0140-6736(23)00221-0. doi: 10.1016/S0140-6736(23)00221.
    PubMed     Abstract available

    December 2022
  17. ADAMS SJ, Stone E, Baldwin DR, Vliegenthart R, et al
    Lung cancer screening.
    Lancet. 2022 Dec 20:S0140-6736(22)01694-4. doi: 10.1016/S0140-6736(22)01694.
    PubMed     Abstract available

    September 2022
    COPD: from an end-stage disease to lifelong lung health.
    Lancet. 2022;400:863.

    April 2022
  19. SAJI H, Okada M, Tsuboi M, Nakajima R, et al
    Segmentectomy versus lobectomy in small-sized peripheral non-small-cell lung cancer (JCOG0802/WJOG4607L): a multicentre, open-label, phase 3, randomised, controlled, non-inferiority trial.
    Lancet. 2022;399:1607-1617.
    PubMed     Abstract available

    Cancer care: beyond survival.
    Lancet. 2022;399:1441.

    September 2021
  21. FELIP E, Altorki N, Zhou C, Csoszi T, et al
    Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial.
    Lancet. 2021 Sep 17. pii: S0140-6736(21)02098.
    PubMed     Abstract available

    Adjuvant PD-L1 blockade in non-small-cell lung cancer.
    Lancet. 2021 Sep 17. pii: S0140-6736(21)02100.

    July 2021
  23. BAAS P, Scherpereel A, Nowak AK, Oukessou A, et al
    Heterogeneity of treatment effects in malignant pleural mesothelioma - Authors' reply.
    Lancet. 2021;398:302.

  24. DI MAIO M, Tagliamento M
    Heterogeneity of treatment effects in malignant pleural mesothelioma.
    Lancet. 2021;398:301-302.

  25. THAI AA, Solomon BJ, Sequist LV, Gainor JF, et al
    Lung cancer.
    Lancet. 2021 Jul 14. pii: S0140-6736(21)00312.
    PubMed     Abstract available

    January 2021
  26. TREASURE T, Macbeth F, Farewell V, Williams NR, et al
    The fallacy of large survival gains from lung metastasectomy in colorectal cancer.
    Lancet. 2021;397:97-98.

Thank you for your interest in scientific medicine.

AMEDEO Lung Cancer is free of charge.